Time filter

Source Type

COLUMBIA, MO, United States

Zambre A.,University of Missouri | Chanda N.,University of Missouri | Prayaga S.,Antibody Research Corporation | Almudhafar R.,University of Lincoln | And 4 more authors.
Analytical Chemistry | Year: 2012

In this paper, we describe a novel strategy for the fabrication of a nanosensor for detecting luteinizing hormone (LH) of sheep using a gold nanoparticle-peptide conjugate. A new peptide sequence "CDHPPLPDILFL" (leutinizing hormone peptide, LHP) has been identified, using BLAST and Clustal W analysis, to detect antibody of LH (sheep). LHP has been synthesized and characterized, and their affinity toward anti-LH was established using enzyme linked immunosorbant assay (ELISA) technique. The thiol group in LHP directly binds with gold nanoparticles (AuNPs) to yield AuNP-LHP construct. Detailed physicochemical analysis of AuNP-LHP construct was determined using various analytical techniques. Nanosensor using gold nanoparticle peptide conjugate was developed on the basis of competitive binding of AuNP-LHP and LH toward anti-LH. Nitrocellulose membrane, precoated with anti-LH, was soaked in the mixture of AuNP-LHP and sample of analysis (LH). In the absence of LH (sheep), anti-LH coated on the membrane binds with AuNP-LHP, leading to a distinctive red color, while in the presence of LH, no color appeared in the membrane due to the interaction of anti-LH with LH thereby preventing the binding of AuNP-LHP with membrane bound anti-LH. The sensor assay developed in this study can detect LH (sheep) up to a minimal concentration of ∼50 ppm with a high degree of reproducibility and selectivity. The gold-nanoparticle-peptide based nanosensor would be a simple, portable, effective, and low cost technique for infield applications. © 2012 American Chemical Society.

Chanda N.,University of Missouri | Shukla R.,University of Missouri | Zambre A.,University of Missouri | Mekapothula S.,University of Missouri | And 10 more authors.
Pharmaceutical Research | Year: 2011

Purpose: The purpose of the present study was to explore the utilization of cinnamon-coated gold nanoparticles (Cin-AuNPs) as CT/optical contrast-enhancement agents for detection of cancer cells. Methods: Cin-AuNPs were synthesized by a "green" procedure, and the detailed characterization was performed by physico-chemical analysis. Cytotoxicity and cellular uptake studies were carried out in normal human fibroblast and cancerous (PC-3 and MCF-7) cells, respectively. The efficacy of detecting cancerous cells was monitored using a photoacoustic technique. In vivo biodistribution was studied after IV injection of Cin-AuNPs in mice, and also a CT phantom model was generated. Results: Biocompatible Cin-AuNPs were synthesized with high purity. Significant uptake of these gold nanoparticles was observed in PC-3 and MCF-7 cells. Cin-AuNPs internalized in cancerous cells facilitated detectable photoacoustic signals. In vivo biodistribution in normal mice showed steady accumulation of gold nanoparticles in lungs and rapid clearance from blood. Quantitative analysis of CT values in phantom model revealed that the cinnamon-phytochemical-coated AuNPs have reasonable attenuation efficiency. Conclusions: The results indicate that these non-toxic Cin-AuNPs can serve as excellent CT/ photoacoustic contrast-enhancement agents and may provide a novel approach toward tumor detection through nanopharmaceuticals. © 2010 Springer Science+Business Media, LLC.

Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 104.91K | Year: 2008

The objective of this proposal is to develop nanoparticulate therapeutic products from the readily injectable Gold-198 (Au-198) nanoconstructs invented at the University of Missouri and licensed to Nanoparticle Biochem, Inc. The Phase I effort embodies three aims: (1) Optimization of synthetic protocols, large scale production, and quality control capabilities of Au-198 nanoparticles (NP) and their utility toward conjugations with Gum Arabic (GA) to produce 198-AuNP-GA for use as an injectable brachy agent in prostate tumor (and various other human cancers) therapy

Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 1.00M | Year: 2010

As part of the SBIR Phase I effort, Nanoparticle Biochem Inc has successfully completed detailed therapeutic efficacy studies of NBI-29 (GA-198AuNP

Kannan R.,University of Missouri | Zambre A.,University of Missouri | Chanda N.,University of Missouri | Kulkarni R.,University of Missouri | And 6 more authors.
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology | Year: 2012

The development of new treatment modalities that offer clinicians the ability to reduce sizes of tumor prior to surgical resection or to achieve complete ablation without surgery would be a significant medical breakthrough in the overall care and treatment of prostate cancer patients. The goal of our investigation is aimed at validating the hypothesis that Gum Arabic-functionalized radioactive gold nanoparticles (GA- 198AuNP) have high affinity toward tumor vasculature. We hypothesized further that intratumoral delivery of the GA- 198AuNP agent within prostate tumor will allow optimal therapeutic payload that will significantly or completely ablate tumor without side effects, in patients with hormone refractory prostate cancer. In order to evaluate the therapeutic efficacy of this new nanoceutical, GA- 198AuNP was produced by stabilization of radioactive gold nanoparticles ( 198Au) with the FDA-approved glycoprotein, GA. This review will describe basic and clinical translation studies toward realization of the therapeutic potential and myriad of clinical applications of GA- 198AuNP agent in treating prostate and various solid tumors in human cancer patients. © 2011 John Wiley & Sons, Inc.

Discover hidden collaborations